ZURA — Zura Bio Ltd

Nasdaq · Health Care · Biotechnology · CIK 1855644 ·
Last close
$5.43
Market Cap
$515.20M
52W High
$6.01
52W Low
$3.25
ADV30
1,296,060
Next earnings
2026-08-13
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and Crebankitug (ZB-168), a fully human immunoglobulin G1 monoclonal antibody targeting interleukin-7 receptor alpha that has completed Phase 1 clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 0 -25,499,000 -24,223,000 228,641,000 225,594,000 11,745,000
Dec 2025 0 -18,411,000 -17,175,000 113,948,000 109,407,000 12,410,000
Sep 2025 0 -19,519,000 -18,040,000 143,935,000 139,017,000 25,491,000
Jun 2025 0 -18,062,000 -15,993,000 157,805,000 154,490,000 18,696,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-64,815,000
Investing CF
$-113,000
Financing CF
$-2,163,000
CapEx
$-113,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-0.83
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-224,547,000
Inventory
Receivables
ST Investments
EBIT TTM
$-75,246,000
Pretax Income TTM
$-68,650,000
Interest Exp TTM
Analysts
6

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 0 -75,246,000 -68,650,000 113,948,000 12,410,000 -64,815,000
Dec 2024 0 -55,189,000 -52,403,000 179,533,000 19,514,000 -28,076,000
Dec 2023 0 -62,638,000 -60,360,000 100,843,000 21,292,000 -15,054,000
Dec 2022 0 -27,162,000 -25,738,000 5,262,000 27,318,000 -1,202,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-0.55

Max Pain — expiry 2026-08-21

max pain strike: $5.00 · spot: $5.43 · call oi: 165 · put oi: 3,171
Expected Move to 2026-08-21: ±$2.65 (48.80%) — implied range $2.78$8.08 · ATM straddle on $5.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
VALN Valneva SE $507.53M $4.97
PRME Prime Medicine, Inc. $527.40M $2.92
TECX Tectonic Therapeutic, Inc. $528.90M $28.03
FDMT 4D Molecular Therapeutics, Inc. $532.17M $10.18
EIKN Eikon Therapeutics, Inc. $498.62M $9.21

News headlines (Yahoo Finance, 1h cache)

Here's Why We're Not Too Worried About Zura Bio's (NASDAQ:ZURA) Cash Burn Situation
2026-06-03 10:09 · Yahoo
One Zura Bio Insider Raised Their Stake In The Previous Year
2026-04-23 10:06 · Yahoo
William Blair Starts Zura Bio (ZURA) at Outperform
2026-07-14 18:09 · Yahoo
Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million
2026-02-25 20:26 · Yahoo
This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges
2026-02-25 20:19 · Yahoo
Disc Medicine Lands New $20 Million Investment as FDA Sets Up Potential Q4 Catalyst
2026-02-25 20:11 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.